Landmarks in hormonal therapy for prostate cancer (Q38050466)

27 August 2017

Landmarks in hormonal therapy for prostate cancer (English)

1 reference

27 August 2017

1 reference

Peter Hammerer

1

1 reference

PubMed ID

23046037

27 August 2017

Stephan Madersbacher

series ordinal

2

1 reference

27 August 2017

1 October 2012

1 reference

27 August 2017

1 reference

27 August 2017

110 Suppl 1

1 reference

27 August 2017

23-29

1 reference

Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer

27 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11431.X

The history of endocrine therapy of benign and malignant diseases of the prostate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11431.X

Leuprolide versus diethylstilbestrol for metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11431.X

Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11431.X

LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11431.X

Differential response of prostate specific antigen to testosterone surge after luteinizing hormone-releasing hormone analogue in prostate cancer and benign prostatic hyperplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11431.X

Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11431.X

Is the flare phenomenon clinically significant?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11431.X

Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11431.X

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11431.X

Hormonal therapy: historical perspective to future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11431.X

A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11431.X

Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11431.X

Nilutamide: possible utility as a second-line hormonal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11431.X

Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11431.X

A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11431.X

BICALUTAMIDE MONOTHERAPY COMPARED WITH CASTRATION IN PATIENTS WITH NONMETASTATIC LOCALLY ADVANCED PROSTATE CANCER: 6.3 YEARS OF FOLLOWUP

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11431.X

Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11431.X

Intermittent versus continuous hormone deprivation in metastatic prostate cancer: preliminary data from an ongoing European study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11431.X

Intermittent androgen suppression for prostate cancer: rationale and clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11431.X

Intermittent androgen blockade in prostate cancer: rationale and clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11431.X

Intermittent androgen castration: a biological reality during intermittent treatment in metastatic prostate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11431.X

Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11431.X

Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11431.X

Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11431.X

Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846--a phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11431.X

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11431.X

Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up (a r

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11431.X

Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11431.X

Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11431.X

Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11431.X

Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11431.X

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11431.X

Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11431.X

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11431.X

Insulin sensitivity during combined androgen blockade for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11431.X

Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11431.X

The genetics, pathophysiology, and management of human deficiencies of P450c17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11431.X

Targeting CYP17: established and novel approaches in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11431.X

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11431.X

Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11431.X

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11431.X

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11431.X

10.1111/J.1464-410X.2012.11431.X

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference

PubMed ID

23046037